![Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing | Scientific Reports Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-17934-6/MediaObjects/41598_2017_17934_Fig1_HTML.jpg)
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing | Scientific Reports
![MabThera 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) MabThera 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~2570~54~image3.png)
MabThera 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)
Tratamiento con rituximab en pacientes con artritis reumatoide en la práctica clínica. Estudio RITAR
![Rituximab en artritis reumatoide: una revisión sistemática de eficacia y seguridad | Reumatología Clínica Rituximab en artritis reumatoide: una revisión sistemática de eficacia y seguridad | Reumatología Clínica](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1699258X11001367:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9184xd8ym1IgxXJ6I4p31f1upH6Ra9/FExf9t4wRA9EIOophxo/0TrOSphP4UKhx1HU9Ql1bd/CXqBJ+vtKMGBt+srBNEPD9cZwuQIYnpn4d1n0PKs5D+QuMKArX3ryvhCJEbPGxyl++utPnW/C0QeD263LWZIfdMA73xJEjHfwy0PP3/6tk1kAiVPHes9je8pGoF5KhWKYONgSEImBt4BVpB+dstMe2N3GfDuS6A4zGQbQVVnlKR2yXbYHg8f42iqcD8jKPaBHSkKZTU876+X0=)
Rituximab en artritis reumatoide: una revisión sistemática de eficacia y seguridad | Reumatología Clínica
![Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01789-0/MediaObjects/41591_2022_1789_Fig1_HTML.png)
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
![783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ 783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ](https://www.eviq.org.au/getmedia/697d4ac9-e60a-4f9c-8492-1097b4f25eb0/Alliance-CALGB-50303-Bartlett-Fig-2.png.aspx)
783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ
![Rituximab in Rheumatoid Arthritis: A Systematic Review of Efficacy and Safety | Reumatología Clínica Rituximab in Rheumatoid Arthritis: A Systematic Review of Efficacy and Safety | Reumatología Clínica](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S217357431100013X:gr3.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9184xd8ym1IgxXJ6I4p31f1upH6Ra9/FExf9t4wRA9EIOophxo/0TrOSphP4UKhx1HU9Ql1bd/CXqBJ+vtKMGBt+srBNEPD9cZwuQIYnpn4d1n0PKs5D+QuMKArX3ryvhCJEbPGxyl++utPnW/C0QeD263LWZIfdMA73xJEjHfwy0PP3/6tk1kAiVPHes9je8pGoF5KhWKYONgSEImBt4BVpB+dstMe2N3GfDuS6A4zGQbQVVnlKR2yXbYHg8f42iqcD8jKPaBHSkKZTU876+X0=)